Smarter data, faster decisions: How biotech funding pressures are reshaping clinical development

Following a turbulent funding environment, biotechs are seeking to generate more data earlier to reassure investors. Following a turbulent funding environment, biotechs are seeking to generate more data earlier to reassure investors. Sponsors have higher expectations of CROs in early-stage trials than ever before, Phippard believes. Credit: KT Stock photos / Shutterstock.com As the biotech sector emerges from a challenging funding cycle, its effects continue to shape how companies design trials, generate data and make go/no‑go decisions. Sponsors are seeking earlier and more comprehensive clinical trial data to attract investment and sustain the development of novel therapies. Chemotherapy in Pharmaceuticals:…

Source: Clinical Trials Arena